A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Gemcitabine (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions
- Sponsors TARIS Biomedical
- 10 Jul 2020 Status changed from active, no longer recruiting to discontinued.
- 13 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 10 Jul 2019 According to a TARIS Biomedical media release, the company announced dosing of the first patient in this phase 1b clinical trial.